Loading
A phase 3 trial of Cabozantinib in thyroid cancer, run by Exelixis, active and no longer recruiting.
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy is a phase 3 interventional study registered as NCT03690388 by Exelixis, with 187 participants enrolled, started 2018-10-05 and due to reach its primary completion in 2020-08-19. Interventions recorded: Cabozantinib, Placebo. Conditions listed: Differentiated Thyroid Cancer. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
187 enrolled.
The CI 5.7 to 0.0 is not 0.0 but NA. The median PFS and upper bound of the CI could not be determined because not enough subjects on the cabozantinib arm had e…; Figures from the ClinicalTrials.gov results section (first posted 2023-05-18), not from a publication · 96% CI 1.8 to 3.6
Source99% CI 5.8 to 29.3; Figures from the ClinicalTrials.gov results section (first posted 2023-05-18), not from a publication · 99% CI 0.0 to 14.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Cabozantinib | 125 | The CI 5.7 to 0.0 is not 0.0 but NA. The median PFS and upper bound of the CI could not be determined because not enough subjects on the cabozantinib arm had e…; Figures from the ClinicalTrials.gov results section (first posted 2023-05-18), not from a publication | 0.22 | <0.0001 | link |
| Placebo | 62 | 1.9 months | ||||
| Objective Response Rate (ORR)primary | Cabozantinib | 67 | 15% | - | - | link |
| Placebo | 33 | 0% |
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Thyroid cancer, Anti-angiogenic therapy.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib.
Shares Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.